Trial
NCT04516811
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
South African National Blood Service
Collaborators
—
Condition
COVID-19
Intervention
COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
Why stopped
No benefit seen in 2 published inpatient RCTs (but had limitations). Press release from inpatient Recovery trial with large number of endpoints showed no benefit. CCP collected from survivors of original strain infection had no neutralisation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-08